10:55 AM EST - Prometic Life Sciences Inc. : Announced that Health Canada has granted priority review status for the New Drug Submission the company plans to file for its plasminogen replacement therapy (RyplazimTM) for the treatment of patients with plasminogen deficiency. Prometic Life Sciences Inc.
shares T.PLI are trading up $0.02 at $1.62.
